| Filed On | Filing |
|---|---|
| 22 Jun 2026 |
8-K/A: Regulation FD Disclosure
Reminder: Lisa Conte, Jaguar’s founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company’s crofelemer development program for rare intestinal failure diseases; click here to regi... |
| 12 Jan 2026 |
8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATIO... |
| 25 Apr 2025 |
8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
On January 29, 2025, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “Note Amendment”) with Streeterville Capital, L... |
| 24 Aug 2022 |
8-K/A: Financial Statements and Exhibits
Certain information marked as [****] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
| 14 Jan 2021 | 8-K/A: Financial Statements and Exhibits |
| 04 Dec 2020 | 8-K/A: Unregistered Sales of Equity Securities |
| 27 Nov 2020 | 8-K/A: Unregistered Sales of Equity Securities |
| 09 Oct 2020 | 8-K/A: Unregistered Sales of Equity Securities |
| 13 May 2020 | 8-K/A: Other Events |
| 27 Jan 2020 | 8-K/A: Entry into a Material Definitive Agreement |
| 12 Jul 2019 | 8-K/A: Unregistered Sales of Equity Securities |
| 28 Jun 2019 | 8-K/A: Unregistered Sales of Equity Securities; Regulation FD Disclosure |
| 26 Mar 2019 | 8-K/A: Financial Statements and Exhibits |
| 29 Aug 2018 | 8-K/A: Other Events |
| 11 Jun 2018 | 8-K/A: Financial Statements and Exhibits |
| 14 Sep 2017 | 8-K/A: Other Events |
| 04 Aug 2017 | 8-K/A: Other Events |
Loading...
